100% Quality Guarantee
PhD-Level Technical Support
Key Features

Guselkumab Biosimilar (IL23A) Antibody (HDBS0146)

SKU HDBS0146
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein IL-23A
Reactivity Human
Host Species Humanized
Isotype IgG1
€431

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Guselkumab Biosimilar (IL23A) Antibody (HDBS0146)

The Guselkumab Biosimilar IL23A Antibody is a cutting-edge product designed for researchers studying interleukin-23 (IL-23) in immune regulation. This monoclonal antibody targets IL-23A, a key cytokine involved in inflammatory responses and autoimmune diseases. The antibody is produced using advanced biosimilar technology, ensuring high specificity and sensitivity in binding to IL-23A.Ideal for use in ELISA, Western blot, and immunohistochemistry applications, the Guselkumab Biosimilar IL23A Antibody enables precise detection and quantification of IL-23A in various sample types. Its unique ability to neutralize IL-23A activity makes it a valuable tool for investigating the role of IL-23A in diseases such as psoriasis, inflammatory bowel disease, and rheumatoid arthritis.

With its proven efficacy and reliability, the Guselkumab Biosimilar Anti-IL23A Antibody is a must-have for researchers seeking to deepen their understanding of IL-23A signaling pathways and develop novel therapeutic approaches targeting IL-23A-mediated immune dysregulation. Invest in this innovative antibody today and accelerate your research progress in the field of immunology and autoimmune disorders.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose